Revolution Medicines (Revolution Medicines) Minority Interest : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Revolution Medicines Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Revolution Medicines's minority interest for the quarter that ended in Dec. 2023 was $0.00 Mil.

Revolution Medicines Minority Interest Historical Data

The historical data trend for Revolution Medicines's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revolution Medicines Minority Interest Chart

Revolution Medicines Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Minority Interest

Get a 7-Day Free Trial

Revolution Medicines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Minority Interest	Get a 7-Day Free Trial															-	-	-	-	-

Revolution Medicines Minority Interest Calculation

Revolution Medicines (Revolution Medicines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revolution Medicines Inc (NAS:RVMD) » Definitions » Minority Interest

Comparable Companies

Traded in Other Exchanges

42Z:Germany

Address

700 Saginaw Drive, Redwood City, CA, USA, 94063

Website

https://www.revmed.com

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Executives

Stephen Michael Kelsey	officer: See Remarks	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Jeff Cislini	officer: General Counsel	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark A Goldsmith	director, officer: See Remarks	925 PAGE MILL ROAD, PALO ALTO CA 94304
Margaret A Horn	officer: See Remarks	925 PAGE MILL ROAD, PALO ALTO CA 94304
Jack Anders	officer: Chief Financial Officer	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Barbara Weber	director	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Xiaolin Wang	officer: See Remarks	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Thilo Schroeder	director	C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001
Lorence H. Kim	director	C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Sushil Patel	director	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801
Third Rock Ventures Iii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Flavia Borellini	director	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Third Rock Ventures Ii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Peter Svennilson	director, 10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Vincent A. Miller	director	C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139